ClinicalTrials.gg

Program

Lamivudine

Also written as “Lamivudine/Zidovudine”, “Lamivudine (3TC)” and “lamivudine”.

Its studies are mostly in HIV Infections · Acquired Immunodeficiency Syndrome · Hepatitis B, Chronic · Infections · Hepatitis B, led by 5 companies.

Furthest: phase 4, since Feb 15, 200049 company-led studies, 2 open or runningNext primary completion: Sep 14, 2032 (phase 3)

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
GlaxoSmithKline352 open or runningphase 4since Feb 15, 2000Nov 2, 1999Sep 14, 2032phase 3 · NCT07393659
Bristol-Myers Squibb70 open or runningphase 4since Jun 27, 2005Nov 2, 1999none ahead
Abbott40 open or runningphase 3since Nov 2, 1999Nov 2, 1999none ahead
Dupont Merck20 open or runningphase 3since Nov 2, 1999Nov 2, 1999none ahead
triangle-pharmaceuticals10 open or runningphase 3since Nov 2, 1999Nov 2, 1999none ahead

Also a collaborator on its studies: ppd-development-lp and dupont-applied-biosciences.

How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

Before these, 33 studies since Nov 2, 1999.

  1. Jun 13, 2012Phase 3 study in HIVBristol-Myers Squibb · NCT01620944 · 3 enrolled
  2. Jul 25, 2013Phase 3 study in InfectionsGlaxoSmithKline · NCT01910402 · 499 enrolled · United States, Argentina, Canada and more
  3. Apr 3, 2014Phase 3 study in InfectionsGlaxoSmithKline · NCT02105987 · 555 enrolled · United States, Canada, Puerto Rico
  4. Dec 14, 2015Phase 4 study in InfectionsGlaxoSmithKline · NCT02634073 · 16 enrolled · United States
  5. Apr 11, 2016Phase 1 study in InfectionsGlaxoSmithKline · NCT02738931 · 30 enrolled · United States
  6. Jul 8, 20162 phase 3 studies in InfectionsGlaxoSmithKline · NCT02831764, NCT02831673
  7. Mar 8, 2017Phase 1 study in InfectionsGlaxoSmithKline · NCT03078556 · 154 enrolled · United States
  8. Jan 5, 2018Phase 3 study in HIV InfectionsGlaxoSmithKline · NCT03446573 · 743 enrolled · United States, Australia, Belgium and more
  9. Sep 21, 2018Phase 3 study in HIV InfectionsGlaxoSmithKline · NCT03682848 · 32 enrolled · Kenya, South Africa, Thailand
  10. May 8, 2019Phase 3 study in HIV InfectionsGlaxoSmithKline · NCT03945981 · 131 enrolled · United States
  11. Jul 11, 2019Phase 3 study in HIV InfectionsGlaxoSmithKline · NCT04021290 · 493 enrolled · United States, Argentina, Belgium and more
  12. Jun 9, 20232 phase 3 studies in HIV InfectionsGlaxoSmithKline · NCT05911360, NCT05917509
  13. Jul 19, 2023Phase 3 study in HIV InfectionsGlaxoSmithKline · NCT05979311 · 463 enrolled · Argentina, Belgium, Denmark and more
  14. Jan 30, 2026Phase 3 study in HIV InfectionsGlaxoSmithKline · NCT07393659 · 197 planned · Romania, South Africa, Uganda

Ahead

  1. Sep 14, 2032Primary completion: phase 3 study in HIV InfectionsGlaxoSmithKline · NCT07393659

TargetBeta

A vaccine: it acts on a pathogen, not a human gene.

“Human immunodeficiency virus type 1 reverse transcriptase inhibitor”ChEMBL 37, by rule

Studies

All 49 led by companies developing it, newest first. Each opens its study page.

StudyPhaseStatusLed byPrimary completionSize
NCT07393659HIV Infections · Romania, South Africa, Uganda3RecruitingGlaxoSmithKlineSep 14, 2032197
NCT05979311HIV Infections · Argentina, Belgium, Denmark and more3Active, not recruitingGlaxoSmithKlineApr 15, 2026463
NCT05917509HIV Infections · United States, Argentina, Canada and more3CompletedGlaxoSmithKlineSep 16, 2025171
NCT05911360HIV Infections · United States, Austria, Belgium and more3CompletedGlaxoSmithKlineJan 23, 2026205
NCT04021290HIV Infections · United States, Argentina, Belgium and more3CompletedGlaxoSmithKlineApr 23, 2021493
NCT03945981HIV Infections · United States3CompletedGlaxoSmithKlineApr 29, 2020131
NCT03682848HIV Infections · Kenya, South Africa, Thailand3CompletedGlaxoSmithKlineDec 1, 202132
NCT03446573HIV Infections · United States, Australia, Belgium and more3CompletedGlaxoSmithKlineMay 20, 2019743
NCT03078556Infections · United States1CompletedGlaxoSmithKlineAug 18, 2017154
NCT02831764Infections · United States, Argentina, Australia and more3CompletedGlaxoSmithKlineApr 4, 2018722
NCT02831673Infections · United States, Argentina, Australia and more3CompletedGlaxoSmithKlineMar 29, 2018719
NCT02738931Infections · United States1CompletedGlaxoSmithKlineJun 201630
NCT02634073Infections · United States4CompletedGlaxoSmithKlineMar 1, 201616
NCT02105987Infections · United States, Canada, Puerto Rico3CompletedGlaxoSmithKlineApr 2015555
NCT01910402Infections · United States, Argentina, Canada and more3CompletedGlaxoSmithKlineSep 22, 2015499
NCT01620944HIV3TerminatedBristol-Myers SquibbJan 22, 20133
NCT00549198Infections · Austria, Belgium, Denmark and more4CompletedGlaxoSmithKlineDec 2009392
NCT00440947Infections · United States, Canada, Puerto Rico3CompletedGlaxoSmithKlineJul 2010515
NCT00410202Hepatitis B, Chronic · United States, Australia, Brazil and more3CompletedBristol-Myers SquibbJan 2011629
NCT00354653Hepatitis B, Chronic · Iran, Islamic Republic of4CompletedGlaxoSmithKlineJan 23, 2007100
NCT00337922HIV Infections · Japan4CompletedGlaxoSmithKline8
NCT00234923HIV Infections3CompletedAbbottFeb 2007138
NCT00140725Hepatitis B, Chronic · Hong Kong3CompletedGlaxoSmithKline160
NCT00135369HIV Infections · United States, Puerto Rico3CompletedBristol-Myers SquibbJul 2005300
NCT00116298HIV Infections · United States, Argentina, Belgium and more3CompletedBristol-Myers SquibbJan 2005900
NCT00116116HIV Infections · United States4CompletedBristol-Myers SquibbJun 200570
NCT00085943HIV Infections · United States, Austria, Belgium and more3CompletedGlaxoSmithKline866
NCT00046176Infections · United States, Costa Rica, Panama and more3CompletedGlaxoSmithKlineMay 17, 2004240
NCT00043953HIV Infections · United States, Canada2CompletedAbbott30
NCT00038220HIV Infections · United States2CompletedAbbott40
NCT00013897HIV Infections · United States, Austria, Belgium and more3CompletedBristol-Myers SquibbApr 2003
NCT00011895HIV Infections · United States4UNKNOWNGlaxoSmithKline400
NCT00009061HIV Infections · United States3UNKNOWNGlaxoSmithKline624
NCT00005106HIV Infections · United States4CompletedGlaxoSmithKline230
NCT00004981HIV Infections · United States3UNKNOWNGlaxoSmithKline230
NCT00004852HIV Infections · United States, Argentina, Brazil and more2CompletedGlaxoSmithKline
NCT00004585HIV Infections · United States4CompletedGlaxoSmithKline40
NCT00004583HIV Infections · United States, Australia, Austria and more3CompletedAbbott660
NCT00002442HIV Infections · United States2CompletedGlaxoSmithKline
NCT00002436HIV Infections · United States, Canada, Puerto Rico3CompletedGlaxoSmithKline325
NCT00002416HIV Infections · United States3Completedtriangle-pharmaceuticals390
NCT00002410HIV Infections · United States, Puerto Rico3CompletedDupont Merck
NCT00002409HIV Infections · United States3CompletedGlaxoSmithKline200
NCT00002391HIV Infections · United States3CompletedGlaxoSmithKline
NCT00002389HIV Infections · United States, Canada, Puerto Rico3CompletedGlaxoSmithKline210
NCT00002371HIV Infections · United States, Canada, Puerto Rico3CompletedBristol-Myers SquibbDec 199780
NCT00002320HIV Infections · United States, Canada, Puerto Rico3CompletedGlaxoSmithKline320
NCT00002227HIV Infections · United States2CompletedDupont Merck60
NCT00002108HIV Infections · United States–CompletedGlaxoSmithKline

How it is read

Names in the registry

  • “Lamivudine”, 35 entries
  • “Lamivudine/Zidovudine”, 6 entries
  • “Lamivudine (3TC)”, 4 entries
  • “lamivudine”, 3 entries
  • “DTG/3TC”, 2 entries

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.